Cofact

Cofact is a specialized pharmaceutical product containing human coagulation factors and proteins, designed to support blood clotting processes. This intravenous medication is manufactured by Prothya Biosolutions Netherlands B.V. and is intended for use in specific medical conditions related to coagulation.

Cofact is primarily used to manage conditions where there is a deficiency in certain coagulation factors. This medication contains human coagulation factor IX, protein C, human coagulation factor VII, protein S, and human coagulation factor V. It is often administered to patients who require support in blood clotting mechanisms, particularly those with inherited or acquired coagulation disorders.

When administered as directed, Cofact works to supplement the body's natural clotting process. This can help reduce the risk of excessive bleeding in individuals with coagulation factor deficiencies. The effects of Cofact are typically observed shortly after intravenous administration, providing rapid support to the body's clotting mechanisms.

Cofact should be handled with care and administered by healthcare professionals experienced in the use of coagulation factors. It is important to follow proper storage and handling guidelines to maintain the integrity of the product. Patients should be monitored for any adverse reactions during and after administration.

Cofact may interact with other medications that affect blood clotting, including anticoagulants and antiplatelet drugs. It is important to inform healthcare providers about all medications being taken to avoid potential interactions. Additionally, patients with known allergies to any of the components in Cofact should exercise caution.